Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Caliper Technologies - CALP -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (106)	10/3/2007 11:15:22 AM
From: tuck	Read Replies (2) \| Respond to of 114

>>Well I liked XGEN when it was by itself. I have a hard problem getting my mind around the business model of CALP with the XGEN acquisition however.<< Caliper seems to be getting some mileage from the Xenogen acquisition. I don't pay much attention, but my Mom does own a bit of CALP, both through direct buying and through the XGEN munch, so I check on CALP once in a while. I haven't found out what happened to the lawsuit with AntiCancer, but here's a couple of recent items. . . . >>Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million Wednesday October 3, 10:18 am ET -- Caliper Discovery Alliances & Services to Develop Customized Transgenic and Knock-Out Mouse Models -- HOPKINTON, Mass., Oct. 3 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News) today announced that the National Institute of Environmental Health Services (NIEHS) has awarded the company a contract valued at up to $7.0 million covering a period of up to ten years at the option of NIEHS. Under the terms of the agreement, Xenogen Biosciences, the in vivo drug discovery services arm of Caliper Discovery Alliances & Services (CDAS), will supply numerous NIEHS investigators with genetically-modified mouse models for research purposes. The NIEHS focuses its research on the environment and its impact on human health and disease. Working with genetically modified mouse models, including transgenic and gene knockout, enables NIEHS to conduct research aimed at identifying and potentially preventing hazardous conditions and exposure in humans. Beginning immediately, Caliper will develop unique mouse models based on the needs of the research teams at the NIEHS. The business was awarded to Caliper through a competitive bid process and reflects the company's expertise and proven ability to design and produce genetic modifications in mice. Caliper has produced more than 9,000 unique mouse and rat models, some of which were previously supplied to the NIEHS under the terms of a previous multi-year agreement. "This contract is the second significant win for our services business in recent months, following the in vitro Environmental Protection Agency contract announced earlier in the second quarter," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Our contract with the NIEHS builds on our existing relationship with this organization and further validates the capabilities of our services organization and the increasing industry demand that is fueling our growth." Caliper Discovery Alliances & Services (CDAS) is the services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services. NovaScreen was acquired by Caliper in October 2005 and Xenogen was acquired by Caliper in August 2006. CDAS provides a wide range of in vitro and in vivo products and services that enable biotechnology and pharmaceutical companies to reduce costs while accelerating the pace and clinical relevance of drug research.<< >>Caliper Life Sciences Grants Multi-Year Imaging Patent License Monday August 13, 8:00 am ET - Caliper's Optical Imaging Patent Suite(TM) Enhances Drug Discovery Efforts - HOPKINTON, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News) today announced that Novartis has signed a multi-year license to Caliper's patented non-invasive optical imaging methods. Non-invasive optical imaging, an increasingly critical technology for drug discovery and development, allows scientists to visualize, track and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost. Caliper, the industry leader in small animal optical imaging solutions, provides commercial and academic customers with an impressive selection of in vivo offerings including imaging systems, reagents, applications, proprietary methods and services that improve drug discovery and development efforts. "This multi-year agreement further validates the importance and relevance of Caliper's optical imaging technology and intellectual property," said Kevin Hrusovsky, chief executive officer, Caliper Life Sciences. "More than 70% of major pharmaceutical companies, and 60% of major biotech companies, now hold a license to the Caliper Optical Imaging Patent Suite, and smaller biotechs are following suit in increasing numbers." Hrusovsky added, "Our recent notification of allowance of patent claims for conjugate fluorescence imaging methods from the U.S. Patent and Trademark Office has significantly increased the value of Caliper's intellectual property estate and complements Caliper's aggressive investment in conjugate probe development." Caliper's Xenogen family of IVIS® instrument systems, reagents, and proprietary methods deliver non-invasive in vivo imaging along with high sensitivity, ease of use and exceptional data quality. Caliper has placed over 450 units to date and recently launched the new Xenogen IVIS Spectrum(TM) system, the first system to provide state-of-the-art bioluminescence and fluorescence capability in a single unit.<< snip Of course, CALP is just kind of sitting there, share price-wise. One does wonder how XGEN would have done independently. I'd guess a little better than CALP has in that time frame. Cheers, Tuck